Annual report pursuant to Section 13 and 15(d)

Acquisition (Details Narrative)

v3.19.3.a.u2
Acquisition (Details Narrative) - USD ($)
12 Months Ended
Oct. 04, 2017
Dec. 31, 2018
Dec. 31, 2019
Dec. 23, 2019
Number of shares issued in exchange for license agreement   298,615    
Common stock shares issued   5,525,009 5,486,476  
Common stock shares outstanding   5,525,009 5,486,476 38,404,530
Promet Therapeutics LLC [Member]        
Business acquisition exchange percentage 90.00%      
Number of shares issued in exchange for net assets 4,535,121      
Business acquisition acquired value $ 1,017,342      
Common stock shares issued 5,039,033      
Common stock shares outstanding 5,039,033      
Equity ownership percentage 84.00%      
Percentage of common stock holdings held for others 6.00%      
Voting interest 90.00%      
Promet Therapeutics LLC [Member] | General and Administrative [Member]        
Acquisition related transaction costs $ 58,763